

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Hematology</b>				
Transfusion	Major histocompatibility complex class I A (HLA-A); HLA-B; HLA-C	<i>In vitro</i> and mouse studies suggest transfusion with HLA-A/B/C <sup>-</sup> platelets generated from induced pluripotent stem (iPS) cells could help decrease platelet transfusion failures in patients with anti-HLA antibodies. <i>In vitro</i> , platelets generated from normal iPS cells aggregated in response to thrombin within 6 minutes but showed a weaker aggregation response than peripheral blood platelets. <i>In vitro</i> , platelets generated from iPS cells that lack HLA-A/B/C had an activation capacity comparable to platelets generated from iPS cells that express HLA-A/B/C. Next steps include optimizing the platelet differentiation method and assessing the safety and tumorigenicity of the iPS cell-derived platelets.	Patent application filed; available for licensing	Feng, Q. <i>et al. Stem Cell Reports</i> ; published online Oct. 16, 2014; doi:10.1016/j.stemcr.2014.09.010 <b>Contact:</b> Robert Lanza, Advanced Cell Technology Inc., Marlborough, Mass. e-mail: <a href="mailto:rlanza@advancedcell.com">rlanza@advancedcell.com</a>
<p><b>SciBX 7(43); doi:10.1038/scibx.2014.1261</b>                      Published online Nov. 6, 2014</p>				